Elekta AB (publ) (EKTAY) Stock Price, News & Analysis

Company Overview

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Key Stats

• Today's Range: $4.93 to $5.09
• 50-Day Range: $4.54 to $5.75
• 52-Week Range: $4.36 to $8.24
• Volume: 4,446 shs
• Average Volume: 18,940 shs
• Market Capitalization: $1.89 billion
• P/E Ratio: 19.74
• Dividend Yield: 2.23%
• Price Target: N/A
• Consensus Rating: Hold

EKTAY Stock Analysis - Frequently Asked Questions

How have EKTAY shares performed this year?

Elekta AB (publ)'s stock was trading at $5.66 at the beginning of 2025. Since then, EKTAY shares have decreased by 12.8% and is now trading at $4.9340.
View the best growth stocks for 2025 here.

How were Elekta AB (publ)'s earnings last quarter?

Elekta AB (publ) (OTCMKTS:EKTAY) issued its quarterly earnings results on Friday, February, 21st. The company reported $0.08 EPS for the quarter, missing analysts' consensus estimates of $0.09 by $0.01. The firm earned $416.86 million during the quarter, compared to analyst estimates of $435.89 million. Elekta AB (publ) had a trailing twelve-month return on equity of 11.07% and a net margin of 5.65%.

How do I buy shares of Elekta AB (publ)?

Shares of EKTAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 2/21/2025
• Record date for 3/27 Dividend: 3/07/2025
• Ex-Dividend for 3/27 Dividend: 3/07/2025
• Dividend Payable: 3/27/2025
• Today: 5/08/2025
• Next Earnings (Estimated): 6/04/2025
• Fiscal Year End: 4/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:EKTAY
• CIK: 1451160
• Web: www.elekta.com
• Phone: (685) 872-5400
• Fax: 46-8-587-255-00
• Employees: 4,718
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $0.25
• Trailing P/E Ratio: 19.40
• Forward P/E Ratio: 13.47
• P/E Growth: N/A
• Net Income: $122.52 million
• Net Margins: 5.65%
• Pretax Margin: 7.33%
• Return on Equity: 11.07%
• Return on Assets: 3.70%

Debt

• Debt-to-Equity Ratio: 0.60
• Current Ratio: 1.05
• Quick Ratio: 0.81

Sales & Book Value

• Annual Sales: $1.70 billion
• Price / Sales: 1.09
• Cash Flow: $0.49 per share
• Price / Cash Flow: 9.86
• Book Value: $2.64 per share
• Price / Book: 1.84

Miscellaneous

• Outstanding Shares: 383,568,000
• Free Float: 225,231,000
• Market Cap: $1.86 billion
• Optionable: Not Optionable
• Beta: 1.26